Immunic, Inc. · NASDAQ:IMUX
Immunic — Cantor Global Healthcare Conference 2019
31 slides from Immunic's conference presentation, Oct 4, 2019
Slide 1: Immunic Therapeutics: Developing Selective Oral Drugs in Immunology
Immunic THERAPEUTICS Immunic Therapeutics Developing Selective Oral Drugs in Immunology NASDAQ: IMUX 4 ad Cantor Global Healthcare Conference — October 4, 2019
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements + Certain statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21€ of the Securities and Exchange Act of 1934, 2s amended, and the Private Securities
Slide 3: Our Vision
G Our Vision We are developing new therapies with best-in-class potential for the treatment of chronic inflammatory and autoimmune diseases. © |mmunic ©immunic,Inc. 02.10.19
Slide 4: Key Investment Highlights
Key Investment Highlights Three potential best-in- class oral therapies High value markets Strong IP position Experienced global management team Strong balance sheet Immunic ~~ — ——SS——S IMU-838: Potent DHODH inhibitor currently tested in three phase 2 studies IMU-935: High demand target with substa
Slide 5: Immunic Leadership Team
Immunic Leadership Team Company is led by an experienced management team Daniel Vitt, PhD Andreas Muehler, MD, MBA Hella Kohlhof, PhD Manfred Groeppel, PhD —_—Sanjay S. Patel, CFA CEO & President co cso coo CFO Renowned international board of directors G908e Duane Nash, MD, JD, MBA Joerg Neermann, P
Slide 6: Development Pipeline
Development Pipeline Preclinical Phase 1 Phase 2 Phase 3 IMU-838. IMU-935, IMU-856 Immunic THERAPEUTICS Multiple Sclerosis DHODH Ulcerative Colitis DHODH Crohn’s Disease DHODH PSC DHODH Psoriasis RORYt Orphan Al Diseases ROBYE el Intestinal Barrier Function Investigator-Sponsored Trial performed at
Slide 7: IMU-838 in Multiple Sclerosis
Immunic THERAPEUTICS IMU-838 in Multiple Sclerosis Mode of Action of IMU-838 Enables Broad Therapeutic Use
Slide 8: Mode of Action: DHODH Targeting Leads to Metabolic Stress
Mode of Action: DHODH Targeting Leads to Metabolic Stress in Metabolically Activated Cells Resting Lymphocyte Activated Lymphocyte Stressed Lymphocyte Pharmacological Effects e) -Metabolically silent -DHODH is functionally not important Disease related activation 4, Insufficient pyrimidine recycling
Slide 9: MS Opportunity
MS Opportunity has the potenti Aubagio” (teriflunomide) is currently the only approved DHODH inhibitor for MS © Immunic 47 hap Pg nfo 352938/8/2233801/878957 POF Accessed Apl3, 2019 ©lmmunic,Ine. 02.10.19
Slide 10: IMU-838: Potential Advantages in MS
IMU-838: Potential Advantages in MS ¢ Potential advantages of IMU-838 therapy compared with Aubagio’ (teriflunomide): * Selectivity and sensitivity (2) 31 (4) * Pharmacokinetic parameters! [4 * Safety profile!?) 9) (91 20) * Drug-drug interaction potential! {1 FOA COER Pharmacologica Review Terfluro
Slide 11: IMU-838: Phase 2 Clinical Trial in RRMS
IMU-838: Phase 2 Clinical Trial in RRMS Phase 2 trial in patients with relapsing-remitting multiple sclerosis (RRMS)* Study Design * Planning to enroll 195 patients in four countries * Primary endpoint: cumulative number of combined unique active (CUA) MRI lesions, up to week 24 * Central reading of
Slide 12: IMU-838 in Inflammatory Bowel Disease (IBD)
Immunic THERAPEUTICS IMU-838 in Inflammatory Bowel Disease (IBD) New Oral Treatment with Promising Safety Profile
Slide 13: IBD: Therapeutic Pyramid
La) IBD: Therapeutic Pyramid Surgery Severe TNFa-mABs Vedolizumab Selective Immunomodulators Traditional Moderate Immunomodulators Severity of Disease Corticosteroids Mild Budesonide Aminosalicylates, Antibiotics Immunic THERAPEUTICS © Immuni, Inc. 02.10.19
Slide 14: IMU-838: Key Strengths That Address Limitation of Existing Therapies in IBD
IMU-838: Key Strengths That Address Limitation of Existing Therapies in IBD No clinical evidence of increased rate of viral re-activations — in-vitro data of direct anti-viral effect Small molecule with low production costs Once daily oral drug intake — beneficial for patients and could improve comp
Slide 15: IBD Phase 2a ENTRANCE: Primary Efficacy Results
IBD Phase 2a ENTRANCE: Primary Efficacy Results 30 ENTRANCE study:!2/ Non-Responders (11.5%) * Study performed 2 with active moiety vidofludimus 26 9 Partial Responders (34.6%) 20 * All patients failed as two attempts to taper down steroids s 88.5% ié Total Response mitt) Number of Patients Complete
Slide 16: IMU-838: Clinical Phase 2 in UC Ongoing
IMU-838: Clinical Phase 2 in UC Ongoing ¢ Active IND in the US; study started in April 2018 * Study design® * Central endoscopy assessment for active disease for study eligibility in order to reduce placebo rate * Endpoint measuring proportion of patients with symptomatic remission and endoscopic he
Slide 17: IBD: Overall Study Program
IBD: Overall Study Program Final 1° Two phase 1 trials Ulcerative colitis (UC) trial UC efficacy analysis Preparation of phase 2 trial in CD based on interim dosing analysis in UC ongoing Final 1° Crohn’s disease (CD) trial CD efficacy analysis © immunic Inc. 02.10.19 v7
Slide 18: IMU-838: Phase 2 Proof-of-Concept Study in PSC
IMU-838: Phase 2 Proof-of-Concept Study in PSC * Ongoing investigator-sponsored trial (IST): Single-arm, open-label, exploratory study planning to enroll 30 patients, aged 18 to 75 years* * Conducted at two Mayo Clinic sites in Arizona and Minnesota by Prof. Keith Lindor, MD, and Elisabeth Carey, MD
Slide 19: IMU-935: Unique RORyt Inverse Agonist
Immunic THERAPEUTICS IMU-935 Unique RORyt Inverse Agonist
Slide 20: Autoimmune Diseases and IMU-935
Autoimmune Diseases and IMU-935 Challenge: Solution: * Autoimmune diseases * IMU-935 is a potent small are frequent diseases affecting molecule targeting RORyt millions of patients worldwide! anti-inflammatory pro-inflammatory * Th17/IL-17/RORyt axis is important in auto immunity related diseases! +
Slide 21: IMU-935: Main Functions of RORyt
IMU-935: Main Functions of RORyt * The differentiation Aueannidas steeon ) [ + IMU-935 towards Th17 cells is inhibited by ® (= kame ee @® @ > = IMU-935. * The production of IL-17A crib »: tue Bock | and IL-17F Prooucion sey ‘yoke peau )p ten is inhibited by IMU-935. e=-6 @=6= * Result: IMU-935 allow
Slide 22: IMU-935: Cytokine Inhibition in Low Nanomolar Range
IMU-935: Cytokine Inhibition in Low Nanomolar Range * Effect of the development compound IM105935 (IMU-935) in stimulated human PBMCs * Inhibition of RORy (20 nM) and DHODH (240 nM) leads to synergistical inhibition of cytokines with ICs9 of 3-5 nM in stimulated human lymphocytes IC5o (HM) IL-17A 0.
Slide 23: IMU-935: Project Status
IMU-935: Project Status * Clinical phase 1 program started in September 2019 * Ongoing double-blind, placebo-controlled, single and multiple ascending dose trials of IMU-935 in healthy volunteers * Extension of these studies to assess safety and mechanism-related biomarkers in patients with mild to
Slide 24: IMU-856: Restoring Intestinal Barrier Function
Immunic THERAPEUTICS IMU-856 Restoring Intestinal Barrier Function
Slide 25: IMU-856: Targeting Gut Barrier Function With New Mode of Action
IMU-856: Targeting Gut Barrier Function With New Mode of Action Healthy Gl Disorders . * IMU-856 is a potent inhibitor A th sages ogen of a novel target which was yy = S| 4 Os validated in a knock-out <Lumen> f eas animal model pace ler i; <lumen> ° Targeting restoration of intestinal barrier functi
Slide 26: IMU-856: Development Plan
IMU-856: Development Plan ¢ Possible GI indications ¢ IBD, IBS-D, ICI * Clinical development plan * Phase 1 single and multiple ascending dose studies are expected to start in H1 2020 ¢ IMU-856 has substantial potential for the treatment of further diseases outside Gl, e.g. CNS ¢ Product is covered
Slide 27: Summary
Immunic THERAPEUTICS Summary
Slide 28: Financial Summary
Financial Summary * Nasdaq: IMUX * Headquarters in San Diego — plan to relocate to East Coast in 2019 * Shares outstanding: 10.0 million (as of August 8, 2019) * Cash position of USD 36.1 million (as of August 8, 2019) * Cash runway expected to be sufficient beyond important value inflection points
Slide 29: Key Investment Highlights — Three Oral Drugs in Development
Key Investment Highlights — Three Oral Drugs in Development IMU-838 currently tested in three phase 2 trials RRMS phase 2 data of IMU-838 expected in Q3 2020 Very promising data from interim dosing analysis of UC phase 2 Three oral programs in active development — each with unique positioning * Phas
Slide 30: i AustraliaMelbourne
i AustraliaMelbourne sma est-in-classdru selectivel B D 2a CO programs g inhibitorsg) 20s one ry > reclinicalS — COs S55 RORY! S854 PECs Ee NASDNOSE 8 S520. bowaebiotecheS io) — extse Bs. SLEDO 3 4 geo IMMUNICES 2:2 “eseg Co*healthcare oy <8 2Simmunology ce piper moleculés > sclerosi is cs Bs DHODHI
Slide 31: Thank You!
Immunic THERAPEUTICS Thank You! Immunic, Inc. 11440 West Bernardo Court, Suite 300 San Diego, CA 92127 USA Jessica, Brew Manager IR & Communications Phone: +49 89 250 0794 69 Email: ir@immunic.de